Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

... studies, and extend the safety database. Two ovarian cancer patients have been enrolled in the study ... Access recently announced data from a recurrent ovarian cancer trial that showed that ProLindac was more ... in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of ...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

... research involving a treatment designed to target ovarian cancer cells otherwise resistant to standard ... being studied in the treatment for women with ovarian cancer who develop a resistance to standard ... study, patients must have platinum-resistant ovarian cancer where the disease has progressed or ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... -The First Presentation of Data on BIBF 1120 in ovarian Cancer- RIDGEFIELD, Conn., May 14 ... BIBW 2992 and a Phase II study of BIBF 1120 in ovarian cancer patients will be presented. LUX ... Presentation of Phase II Data on BIBF 1120 in ovarian Cancer Data from a Phase II study of BIBF ...

Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC

... Technology to improve accuracy of ovarian cancer diagnosis TAMPA, Fla., May 14 ... a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been ... Moffitt and Frantz BioMarkers will collaborate on ovarian cancer biomarker research, combining use of these ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... lymphomas, breast, lung, colon, pancreatic, and ovarian cancer. In preclinical studies, MDX-1338, a fully ... on mesotheliomas and other cancers, including ovarian and lung cancer, and because of its limited ... antibody-drug conjugate. In xenograft models of ovarian and lung cancer, MDX-1204, a fully human ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... in vitro and in vivo studies of EP-100 in ovarian cancer cell lines and ovarian xenograft models were presented in a poster ... "Targeted Oncolytic Peptide for Treatment of ovarian Cancers" at the American Association for Cancer ...

Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA

... USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan Drug designation can entail ... the use of Paclical to Taxol(R) in patients with ovarian cancer. A safety objective is to show the ... Aleksov, CEO of Oasmia in a comment. About ovarian cancer ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this monotherapy study 66% of ... ProLindac as a monotherapy treatment for advanced ovarian cancer, to provide data on the monotherapy ... Ca-125, the established specific serum marker for ovarian cancer, were also observed in several patients. ...

Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis

... in the nationwide Prostate, Lung, Colorectal and ovarian (PLCO) Cancer Screening Trial who were ... laboratory provider of the blood-based HE4 ovarian Cancer Monitoring test, which is FDA cleared as ... or progressive disease in women with epithelial ovarian cancer. The company is also developing a ...

Vermillion Presents Critical Data From Its OVA1 Clinical Trial

... for distinguishing between malignant and benign ovarian tumors" was co-authored by Fred Ueland, MD, ... for distinguishing between malignant and benign ovarian tumors." The primary aim of the study was to ... women who are scheduled for surgery with an ovarian mass. The data demonstrates that the OvaCalc ...

Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass

... for Risk Stratification of Women with Suspected ovarian Cancer MALVERN, Pa., Jan. 26 /PRNewswire/ -- ... as an aid in estimating the risk of epithelial ovarian cancer in premenopausal or postmenopausal women ... blood tests - CA125 and HE4 - and the Risk of ovarian Malignancy Algorithm (ROMA(TM)) to identify ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred ... of DOXIL - In patients with recurrent ovarian cancer or AIDS-related Kaposi's ... doxorubicin HCl * In patients with recurrent ovarian cancer, the most common all-grade adverse ...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

... of voreloxin in advanced platinum-resistant ovarian cancer and that the drug is generally well ... standard of care in AML and platinum-resistant ovarian cancer and look forward to reporting updated ... Phase 2 Trial of Voreloxin in Platinum-Resistant ovarian Cancer In this ongoing Phase 2 study, 65 women ...

Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.

... The OVA1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. ... Distinguishing Between Malignant and Benign ovarian Tumors" was co-authored by scientists at ... and President of Vermillion. About Vermillion's ovarian Cancer Diagnostic Program In addition to ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... of patient recruitment for its Phase 2 trial in ovarian cancer with AEZS-108, a luteinizing ... patients with a diagnosis of platinum-resistant ovarian cancer. The trial is part of a Phase 2 program in ... up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary ...

Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test

... clinical trial was one of the largest ovarian cancer studies ever conducted and assessed more ... thousands of women who require surgery for ovarian tumors each year. This information can be used to ... numerous studies have shown that women with ovarian cancer have better overall outcomes when their ...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... in the acute myeloid leukemia and ovarian cancer indications," said Daniel Swisher, ... at the 44th ASCO Annual Meeting in the Phase 2 ovarian cancer trial demonstrated that 48 percent of platinum-resistant ovarian cancer patients treated at a dose of 48 ...

Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer

... is approved for the treatment of patients with ovarian cancer whose disease has progressed or recurred ... new combination, particularly in those women with ovarian cancer, are promising and warrant further study. Advanced ovarian cancer is among the deadliest cancers, ...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

... of single-agent clinical activity in ovarian cancer patients who have failed prior rounds of ... clinical activity in platinum-resistant ovarian cancer patients. Thus far, of 62 women ... and tolerability among platinum-resistant ovarian cancer patients and we are focused on advancing ...

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium

... Ongoing Clinical Study of ProLindac in Recurrent ovarian Cancer." ProLindac is Access' novel DACH ... study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was ... 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access believes that ProLindac's ...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

... clinical trial of voreloxin in platinum-resistant ovarian cancer patients will be presented during the 44th ... IN WOMEN WITH PLATINUM RESISTANT EPITHELIAL ovarian CANCER Abstract #5582 General poster session Gynecologic Cancer: ovarian Cancer Saturday, May 31, 2008, 8:00 a.m. - ...

Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America

... disease, has begun accepting patients for an ovarian cancer vaccine clinical trial. The Phase ... with chemotherapy-resistant, advanced stage ovarian cancer. The study will be conducted exclusively ... will be CTCA patients who have stage III or IV ovarian cancer and have tumor progression despite at ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... focused on metastatic breast cancer, lung cancer, ovarian cancer, brain cancer, mesothelioma, pancreatic ... (Vista Room) ovarian Cancer in First Relapse ... Poster ovarian Cancer discussion ...

Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting

... Clinical Data from Prostate, Colorectal and ovarian Cancers - - ... of picoplatin in advanced solid tumors, including ovarian cancer. Picoplatin, the Company's lead product ... including those with colorectal, prostate and ovarian cancer. These results should be of significant ...

BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer

... Assess BSI-201 Therapy in BRCA-Negative ovarian Cancer Patients - BRISBANE, Calif., May 8 ... trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of ... portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. ...

BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies

... polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the ... multi-drug resistant xenograft models of ovarian cancer. "We are excited to share emerging data ... in multiple solid tumor settings including ovarian cancer." The data presented at the 2008 ...

Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease

... demonstrating the benefits of the Company's ovarian cancer protein biomarker panel. The data suggest ... of Vermillion. Further Evidence Supporting ovarian Tumor Triage Test (Poster 135) A clinical study examining Vermillion's marker panel for ovarian cancer provided independent validation that it ...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

... product candidate, SNS-595, in platinum-resistant ovarian cancer patients. In this Phase 2 clinical ... to SNS-595 therapy. "Recurrence rates among ovarian cancer patients remain high, and the majority of ... a promising, active agent in a difficult-to-treat ovarian cancer patient population," said William P. ...

Vermillion Receives Award From the Society of Gynecologic Oncologists

... Company to Present New Data on its ovarian Cancer Diagnostics Program at the Society of ... abstract, which demonstrated that the Company's ovarian Tumor Triage Test correctly identified 84 percent of ovarian cancer cases compared to only 33 ...

BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)

... candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing ... days repeated every 3 weeks to advanced ovarian cancer patients who have previously been treated ... completed in the U.S. in patients with advanced ovarian cancer, metastatic malignant melanoma, advanced ...

EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers

... MKC-1, in recurrent or resistant epithelial ovarian cancer and advanced endometrial cancer patients. ... a single agent in platinum or taxane refractory ovarian and endometrial cancer patients. In addition, ... utility in multiple tumor types." About ovarian and Endometrial Cancers ...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

... breast cancer, and in patients with refractory ovarian cancer who were progressing on ... metastatic breast cancer and 3 patients had ovarian cancer (HER2 status unknown). Clinical benefit ... breast cancer. Of the 3 patients with ovarian cancer, 1 patient (13 prior regimens) who was on ...

Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania

... least 30 patients, using DCVax(R)-L for recurrent ovarian cancer, has begun at The University of ... Carl June. The funding is being provided by the ovarian Cancer Vaccine Initiative. (See below for more ... grade 3 or 4 adverse events). This multi-modal ovarian cancer trial has been designed to maintain ...

Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint

... of OvaRex(R) MAb for the treatment of advanced ovarian cancer. Preliminary analysis demonstrates that ... the United States. The studies enrolled 367 ovarian cancer patients and assessed the efficacy of ... it to the finish line as a new therapeutic for ovarian cancer, and we owe a huge debt of gratitude to ...

Biocept Announces Study to Isolate Circulating Tumor Cells from Blood

... cell population. The focus of this study is ovarian cancer. "This innovation in rare cell capture ... an enhanced opportunity to detect circulating ovarian cancer cells," says principal investigator ... isolation of circulating tumor cells (CTCs) in ovarian cancer patients, to quantify the levels of CTCs ...

CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference

... activity of combination IV belinostat in ovarian cancer reported - - ... with carboplatin and paclitaxel for relapsed ovarian cancer, Phase I safety and dose-escalation ... seen with BelCaP for the treatment of relapsed ovarian cancer, including activity against platinum ...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

... candidate, SNS-595, in platinum-resistant ovarian cancer patients. Administered as a single agent, ... activity among platinum-resistant ovarian cancer patients who have also failed treatment ... demonstrate that SNS-595 is a potent inhibitor of ovarian tumor cell growth, with activity ...

Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

... in borderline potentially platinum-sensitive ovarian cancer (OC) patients" on Tuesday, October 23, ... with other cytotoxics, in human colon and ovarian cancer cells." ProLindac is a novel DACH ... in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of ...

CuraGen Announces Top-Line Phase II Results on Velafermin

... for Patients (pts) with Relapsed ovarian Cancer Date: Thursday, October 25, ... Platinum Resistant Epithelial ovarian Tumors and Micropapillary/Borderline (LMP) ovarian Tumors. A Trial of the PMH Phase II ...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

... breast cancer, and in patients with refractory ovarian cancer who were progressing on standard ... regimens prior to this study) and 3 patients had ovarian cancer (HER2 status unknown). Clinical benefit ... 6+, 8 and 10 months). Of the 3 patients with ovarian cancer, -- 1 patient (13 prior regimens) who ...